首页> 美国卫生研究院文献>Molecules >Differential Proteomics Reveals miR-155 as a Novel Indicator of Liver and Spleen Pathology in the Symptomatic Niemann-Pick Disease Type C1 Mouse Model
【2h】

Differential Proteomics Reveals miR-155 as a Novel Indicator of Liver and Spleen Pathology in the Symptomatic Niemann-Pick Disease Type C1 Mouse Model

机译:差异蛋白质组学揭示了miR-155作为有症状的尼曼-皮克病C1型小鼠模型中肝脏和脾脏病理的新指标

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。
获取外文期刊封面目录资料

摘要

Niemann-Pick disease, type C1 (NPC1) is a rare, autosomal recessive, lipid storage disorder caused by mutations in NPC1. As a result, there is accumulation of unesterified cholesterol and sphingolipids in the late endosomal/lysosomal system. Clinically, patients can present with splenomegaly and hepatomegaly. In the current study, we analyzed the differential proteome of the spleen in symptomatic Npc1−/− mice to complement previous studies focused on the differential proteome of the liver, and then evaluated biomolecules that may serve as tissue biomarkers. The proteomic analysis revealed altered pathways in NPC1 representing different functional categories including heme synthesis, cellular regulation and phosphoinositide metabolism in both tissues. Differential proteins included several activators of the ubiquitous and critical protein, Akt, a major kinase involved in multiple cellular processes. Evaluation of Akt revealed decreased expression in both the liver and spleen tissues of symptomatic Npc1−/− mice. Upstream regulation analysis also suggested that miR-155 may modulate the differences of known downstream protein targets observed in our dataset. Upon evaluation of miR-155, we observed an increased expression in the liver and decreased expression in the spleen of symptomatic Npc1−/− mice. Here, we propose that miR-155 may be a novel indicator of spleen and liver pathology in NPC1.
机译:C型Niemann-Pick病(NPC1)是由NPC1突变引起的罕见的常染色体隐性脂质贮积病。结果,在晚期内体/溶酶体系统中积累了未酯化的胆固醇和鞘脂。临床上,患者可出现脾肿大和肝肿大。在本研究中,我们分析了有症状的Npc1 -// 小鼠中脾脏的差异蛋白质组,以补充先前针对肝脏差异蛋白质组的研究,然后评估了可用作组织生物标志物的生物分子。 。蛋白质组学分析揭示了NPC1中代表不同功能类别的途径发生了变化,包括两个组织中的血红素合成,细胞调节和磷酸肌醇代谢。差异蛋白包括普遍存在的关键蛋白Akt(一种参与多种细胞过程的主要激酶)的几种激活剂。对Akt的评估显示,有症状Npc1 -// 小鼠的肝脏和脾脏组织中的表达均降低。上游调节分析还表明,miR-155可以调节我们数据集中观察到的已知下游蛋白靶标的差异。通过对miR-155的评估,我们观察到有症状的Npc1 -// 小鼠在肝脏中的表达增加而在脾脏中的表达减少。在这里,我们建议miR-155可能是NPC1中脾脏和肝脏病理的新指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号